Online inquiry

IVTScrip™ mRNA-Anti-EGFR, GA201(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7419MR)

This product GTTS-WQ7419MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, GA201(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ7419MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5386MR IVTScrip™ mRNA-Anti-env, CD4(178) PE40(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CD4(178) PE40
GTTS-WQ3931MR IVTScrip™ mRNA-Anti-CTLA4, BCD-145(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BCD-145
GTTS-WQ7976MR IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GX-17
GTTS-WQ2341MR IVTScrip™ mRNA-Anti-MS4A1, AME-133v(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AME-133v
GTTS-WQ10284MR IVTScrip™ mRNA-Anti-PCSK9, LGT209(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LGT209
GTTS-WQ15820MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA XmAb14045
GTTS-WQ15823MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA XmAb14045
GTTS-WQ9467MR IVTScrip™ mRNA-Anti-C5AR1, IPH-5401(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IPH-5401
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW